Illumina iSeq 100 Sequencing System CMOS SBS Technology 1.2Gb Data Output
Illumina
Details
-
CategoryMolecular Biology
-
Dimension22.0in x 22.0in x 25.0in
-
SerialFS10000167
-
Shipping TypeFedEx Ground
-
ManufacturingDoes Not Apply
-
Voltage / Hertz100-240V / 50Hz/60Hz
Description
The Illumina iSeq 100 Sequencing System is a high-precision DNA sequencing platform leveraging CMOS technology and SBS chemistry. Designed to generate at least 1.2 Gb of data in 19 hours, this compact sequencer is ideal for detecting rare variants with high accuracy and speed. Presented in new condition with potential cosmetic imperfections, this stand-alone unit includes one power cord and user manuals. The system operates at 100-240V, features built-in RFID for consumables tracking, and operates efficiently within a temperature range of 15-30°C. Compact and self-sufficient, the iSeq 100 is perfect for researchers performing quick, small-scale sequencing runs.
Technician comment
New in open case. Everything in pictures is included. See photos
Key Features
- CMOS technology
- SBS chemistry
- 1.2 Gb output per run
- Compact design
- RFID for consumables tracking
- Temperature range: 15-30°C
- Voltage: 100-240V
Specifications
- Minimum output: 1.2 Gb per run
- Run time: 19 hours
- RFID tracking for consumables
- Control computer: Celeron J1900 2 GHz Quad Core CPU, 8 GB RAM, 240 GB SSD
- Operating System: Windows 10 IoT Enterprise
- Operating temperature: 15°C to 30°C
- Humidity: noncondensing 20%-80% relative humidity
- Power requirements: 100-240 VAC at 50/60 Hz, 80 W
- LED: 520-530 nm, 1.5 W/cm2 at image plane
- RFID frequency: 13.56 MHz, supply current 120 mA
Weight
Imperial: 66.0 Pounds
Metric: 29.94 Kilograms
Shipping Dimensions
Imperial: 26.4 lb x 26.4 lb x 30.0 lb
Metric: 67.06 cm x 67.06 cm x 76.2 cm
Harmonized Code
9027.50.40
Harmonized Code Details
9027.50.40: Instruments and apparatus for physical or chemical analysis. Utilized for DNA sequencing, fitting the description for instruments used in laboratory settings for analysis.
Comments 0
There are currently no public comments.